{{Rsnum
|rsid=8050894
|Gene=VKORC1
|Chromosome=16
|position=31093188
|Orientation=plus
|GMAF=0.4904
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=VKORC1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 44.6 | 36.9 | 18.5
| HCB | 0.0 | 11.1 | 88.9
| JPT | 0.0 | 20.5 | 79.5
| YRI | 54.0 | 41.3 | 4.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 11.1 | 88.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
{{ neighbor
| rsid = 9934438
| distance = 369
}}

rs8050894, is located on chromosome 16 in the gene [[VKORC1]].  VKORC1 is the primary target of the drug [[warfarin]] ([[Coumadin]]), a commonly used oral anticoagulant.  rs8050894 is one of several polymorphisms found in VKORC1 that is associated with specific warfarin doses ({{PMID|15930419}}).  Other polymorphisms in VKORC1 ([[rs7196161]], [[rs9923231]], [[rs9934438]], [[rs2359612]]) are equally predictive of warfarin dose requirement in both European and Asian-descent individuals.

Other polymorphisms found in the gene cytochrome P450 2C9 ([[CYP2C9]]) influence the metabolism of warfarin and have a smaller effect on warfarin dose.  These polymorphisms are [[rs1799853]] (CYP2C9*2) and [[rs1057910]] (CYP2C9*3).

{{PMID|18841283}} In several hundred Europeans, no association was found between [[rs8050894]] and risk for ischemic [[stroke]].

{{PMID Auto
|PMID=19436136
|Title=Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status
|OA=1
}}

{{PharmGKB
|RSID=rs8050894
|Name_s=VKORC1: 1542G>C; 6853G>C
|Gene_s=VKORC1
|Feature=Intron
|Evidence=PubMed ID:16270629
|Annotation=This SNP is the tagging SNP for VKORC1*2.
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162356242
}}

{{PMID Auto
|PMID=21179439
|Title=VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey
|OA=1
}}

{{PMID|17387222|OA=1
}} Genetic-based dosing in orthopedic patients beginning warfarin therapy.

{{PMID|17456829|OA=1
}} Evaluation of genetic factors for warfarin dose prediction.

{{PMID|18252229|OA=1
}} Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

{{PMID|18305455|OA=1
}} Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

{{PMID|18466099|OA=1
}} Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

{{PMID|18523153|OA=1
}} Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

{{PMID|18559094|OA=1
}} Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

{{PMID|18752379|OA=1
}} Warfarin pharmacogenetics.

{{PMID|18809808|OA=1
}} Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

{{PMID|18855533|OA=1
}} VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

{{PMID|19074728|OA=1
}} Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

{{PMID|19228618|OA=1
}} Estimation of the warfarin dose with clinical and pharmacogenetic data.

{{PMID|19955245|OA=1
}} Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

{{PMID|21359226|OA=1
}} The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8050894
|overall_frequency_n=35
|overall_frequency_d=100
|overall_frequency=0.35
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23662025
|Title=Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}